%0 Journal Article
%T Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge
%A Hwi Seo
%A Yeonsu Oh
%A Kiwon Han
%A Changhoon Park
%A Chanhee Chae
%J BMC Veterinary Research
%D 2012
%I BioMed Central
%R 10.1186/1746-6148-8-194
%X A reduction of PCV2 viremia coincided with the appearance of both PCV2-specific neutralizing antibodies (NA) and interferon-¦Ã-secreting cells (IFN-¦Ã-SCs) in the vaccinated animals. However, the presence of anti-PCV2 IgG antibodies did not correlate with the reduction of PCV2 viremia. Lymphocyte subset analysis indicated that the numbers of CD3+ and CD4+ cells increased in vaccinated animals but the numbers of CD4+ cells decreased transiently in non-vaccinated animals. The observation of a delayed type hypersensitivity response in only the vaccinated animals also supports a CD4+ cell-associated protective cellular immune response induced by the reformulated inactivated chimeric PCV1-2 vaccine.The induction of PCV2-specific NA and IFN-¦Ã-SCs, and CD4+ cells by the reformulated inactivated chimeric PCV1-2 vaccine is the important protective immune response leading to reduction of the PCV2 viremia and control of the PCV2 infection. To our knowledge this is the first demonstration of protective humoral and cellular immunity induced by the reformulated inactivated chimeric PCV1-2 vaccine and its effect on reduction of PCV2 viremia by vaccination.Porcine circovirus type 2 (PCV2) is one of the most economically important swine pathogens worldwide. The first commercial PCV2 vaccine was used under special license in France and Germany in 2004, 13 years after postweaning multisystemic wasting syndrome (PMWS) was first identified and reported in western Canada [1]. In addition to PMWS, PCV2 is also associated with a number of diseases and syndromes, collectively referred to as porcine circovirus-associated disease (PCVAD) [2,3].Currently, 5 commercial PCV2 vaccines are available worldwide and differ in their antigen [1]. One vaccine (Circovac, Merial) is based on the classical approach of an inactivated oil-adjuvanted vaccine. Three subunit vaccines (Circoflex, Boehringer Ingelheim; Circumvent PCV, Intervet/Merck; Porcillis PCV, Schering-Plough/Merck) are based on an open readin
%K Chimeric PCV1-2 vaccine
%K Efficacy
%K Humoral and cellular immunity
%K Porcine circovirus-associated disease
%K Porcine circovirus type 2
%K Porcine circovirus vaccine
%U http://www.biomedcentral.com/1746-6148/8/194